Antiemetics Market By Drug Type (Serotonin Antagonists, Dopamine Antagonists, Antihistamines, Others); By Application (Chemotherapy-induced Nausea and Vomiting, Motion Sickness, Other Medical Conditions); By End-Use (Hospitals, Clinics, Home Care Settings) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
The Antiemetics Market size was valued at USD 5125.4 million in 2024 and is anticipated to reach USD 9005.9 million by 2032, at a CAGR of 7.3% during the forecast period (2024-2032).
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Antiemetics Market Size 2024
USD 5125.4 million
Antiemetics Market, CAGR
7.3%
Antiemetics Market Size 2032
USD 9005.9 million
Key drivers of the market include a growing patient base undergoing chemotherapy, the rise in lifestyle diseases, and the increasing awareness about antiemetic treatment options. Technological advancements in drug delivery systems, such as oral disintegrating tablets and transdermal patches, are further contributing to market growth. Additionally, the increasing focus on patient-centric solutions, such as personalized treatment regimens, is expected to boost market demand. The launch of new and more effective antiemetic drugs will also play a key role in market expansion.
Regionally, North America holds a significant share in the antiemetics market, driven by advanced healthcare infrastructure and high adoption of novel drug treatments. Europe follows closely, with a steady demand for antiemetic drugs driven by the increasing number of cancer patients and the availability of effective treatments. The Asia-Pacific region is expected to witness the highest growth rate, attributed to rising healthcare access and the growing burden of diseases requiring antiemetic therapies. Increasing government initiatives to improve healthcare access in emerging economies further support the region’s market growth.
Market Insights:
The antiemetics market is valued at USD 5125.4 million in 2024 and is anticipated to reach USD 9005.9 million by 2032, growing at a CAGR of 7.3%.
Key drivers include a growing patient base undergoing chemotherapy, rising lifestyle diseases, and the increasing awareness of antiemetic treatment options.
Technological advancements in drug delivery systems, such as oral disintegrating tablets and transdermal patches, are boosting market growth by offering improved patient compliance and treatment outcomes.
Personalized treatment regimens, focusing on patient-centric solutions, are driving demand for more targeted therapies to manage nausea and vomiting effectively.
Regulatory and safety concerns remain a challenge, with stringent requirements for drug approval processes and clinical trials delaying the launch of new antiemetic treatments.
The rise of over-the-counter alternatives creates competition, as patients often opt for accessible, affordable options like OTC antiemetics for mild nausea or motion sickness.
North America holds 35% of the global antiemetics market share, followed by Europe at 27%. The Asia-Pacific region is expected to experience the highest growth rate, driven by increasing healthcare access and a growing disease burden.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The increasing number of patients undergoing chemotherapy is a major driver for the antiemetics market. Chemotherapy is known for inducing severe nausea and vomiting, leading to a significant demand for antiemetic drugs to manage these side effects. With the rising number of cancer diagnoses worldwide, especially in North America and Europe, the need for effective antiemetic treatments continues to grow. Advances in chemotherapy regimens further contribute to the heightened need for these medications, particularly as newer treatments show higher effectiveness but may also cause more pronounced side effects. This growth in cancer treatment options will continue to drive the antiemetics market.
For instance, Glenmark Pharmaceuticals launched AKYNZEO I.V. in India, a first-of-its-kind fixed intravenous combination of fosnetupitant (235 mg) and palonosetron (0.25 mg).
Rising Prevalence of Lifestyle Diseases
The global increase in lifestyle-related diseases, such as obesity, diabetes, and gastrointestinal disorders, is significantly impacting the antiemetics market. Conditions like nausea, acid reflux, and motion sickness are commonly associated with these diseases, increasing the demand for antiemetic drugs. With unhealthy dietary habits and sedentary lifestyles becoming more prevalent, more individuals seek relief from symptoms caused by these conditions. This shift in disease burden adds another layer of demand for antiemetic drugs, further fueling market expansion.
Technological Advancements in Drug Delivery Systems
Technological advancements in drug delivery systems are enhancing the efficacy and convenience of antiemetic treatments. The introduction of oral disintegrating tablets and transdermal patches provides patients with more convenient and effective methods of administering antiemetic drugs. These advancements ensure better patient compliance and improved treatment outcomes, particularly in populations with difficulty swallowing pills or those who need continuous medication. As these systems evolve, they are expected to play a pivotal role in the market’s growth, offering personalized solutions to patients’ needs.
For instance, Takeda has developed dexlansoprazole orally disintegrating tablets that demonstrated a mean in-vivo disintegration time of 29 to 43 seconds without water, showcasing an effective formulation for patients.
Increasing Focus on Patient-Centric Solutions
The antiemetics market is also benefiting from an increased focus on patient-centric solutions. Personalized treatment regimens tailored to individual needs enhance the effectiveness of antiemetic therapies. This approach has become more prominent with the growing emphasis on precision medicine, enabling healthcare providers to deliver targeted therapies. By considering factors like genetic makeup, medical history, and lifestyle, these personalized treatments improve the overall management of nausea and vomiting, which contributes to the market’s expansion.
Market Trends:
Shift Towards Novel Drug Formulations and Delivery Methods
The antiemetics market is witnessing a shift towards novel drug formulations and advanced delivery methods. These innovations aim to improve the effectiveness and convenience of treatments, meeting the increasing demand for better patient compliance and outcomes. Newer formulations, such as extended-release tablets and transdermal patches, allow for prolonged relief with fewer side effects, contributing to enhanced patient experiences. Companies are also focusing on the development of oral disintegrating tablets and injectable antiemetics, offering rapid relief for patients who may have difficulty swallowing traditional tablets. The ongoing advancement in these delivery systems helps to address unmet needs in the management of nausea and vomiting, positioning the antiemetics market for sustained growth.
For instance, Heron Therapeutics developed Sustol, an extended-release injectable suspension of granisetron that utilizes a polymer-based drug delivery technology to maintain therapeutic concentrations for at least 5 days.
Expanding Use of Antiemetic Drugs Across Various Therapeutic Areas
Antiemetic drugs are no longer confined to cancer treatment but are increasingly used across a variety of therapeutic areas. The rise in gastrointestinal disorders, motion sickness, and other conditions that induce nausea and vomiting is driving this trend. It is particularly evident in the treatment of diseases like irritable bowel syndrome and gastroparesis, where antiemetics provide essential symptom relief. The growing awareness of the effectiveness of antiemetic therapies in managing nausea associated with these conditions has expanded the market’s application beyond oncology. This broadening scope will continue to enhance the market’s reach, offering new opportunities for growth as the focus shifts towards managing a wider range of symptoms linked to various diseases.
For instance, the drug Emend, manufactured by Merck, contains the active ingredient aprepitant and is approved for preventing postoperative nausea and vomiting at a single oral dose of 40 mg.
Market Challenges Analysis:
Regulatory and Safety Concerns
One of the major challenges facing the antiemetics market is regulatory and safety concerns surrounding the approval of new drugs. Stringent regulatory requirements and safety evaluations can delay the launch of innovative antiemetic treatments. Many drugs in development must undergo extensive clinical trials to ensure their safety and effectiveness, which can be time-consuming and costly. These regulatory hurdles not only delay product availability but also impact market growth. Manufacturers must address concerns related to potential side effects and long-term safety, which adds complexity to the approval process.
Competition from Over-the-Counter Alternatives
The antiemetics market faces significant competition from over-the-counter (OTC) alternatives that are widely available and cost-effective. Many individuals opt for OTC drugs for conditions like motion sickness and mild nausea due to their accessibility and affordability. This trend can hinder the growth of prescription antiemetics, as patients may prefer more accessible treatments that do not require a doctor’s visit. The rise in OTC options, coupled with the increasing awareness of self-medication, challenges pharmaceutical companies in differentiating their prescription antiemetic offerings, limiting market growth in certain regions.
Market Opportunities:
Increasing Demand for Personalized Treatment Options
A key opportunity in the antiemetics market lies in the increasing demand for personalized treatment options. The growing focus on precision medicine presents an opportunity to develop antiemetic therapies tailored to individual patient needs. Advancements in genomics and pharmacogenomics enable healthcare providers to customize treatments based on genetic profiles, improving efficacy and minimizing side effects. By addressing the unique needs of cancer patients, individuals with gastrointestinal disorders, and those suffering from motion sickness, personalized treatments can enhance patient satisfaction and outcomes, expanding the market for antiemetics.
Expansion in Emerging Markets
The expansion of the antiemetics market in emerging economies offers significant growth opportunities. As healthcare infrastructure improves in regions such as Asia-Pacific, Latin America, and the Middle East, the demand for effective antiemetic therapies is expected to rise. These regions are witnessing an increase in lifestyle diseases, cancer prevalence, and overall healthcare access, contributing to a growing need for antiemetic drugs. With rising awareness and the adoption of modern treatment options, these emerging markets present a lucrative opportunity for companies to tap into, fostering long-term growth in the global antiemetics market.
Market Segmentation Analysis:
By Drug Type
The antiemetics market is segmented by drug type into serotonin antagonists, dopamine antagonists, antihistamines, and others. Serotonin antagonists lead the market due to their widespread use in preventing chemotherapy-induced nausea and vomiting. Dopamine antagonists follow closely, offering effective treatment for conditions such as motion sickness and gastrointestinal disorders. Antihistamines, used for mild nausea, are gaining popularity for their over-the-counter availability. The growing demand for targeted treatments and the launch of new drug formulations are expected to further enhance the market for each segment.
For instance, Tris Pharma advanced antihistamine delivery with its Karbinal ER, the first FDA-approved extended-release liquid formulation for children as young as two. This technology allows for effective symptom relief with just a single dose every 12 hours.
By Application
The market is segmented by application into chemotherapy-induced nausea and vomiting, motion sickness, and other medical conditions. Chemotherapy-induced nausea and vomiting represent the largest segment due to the high number of cancer patients undergoing treatment. Motion sickness, particularly in the travel and maritime industries, is another significant application driving market demand. Other applications include nausea from gastrointestinal disorders, pregnancy, and postoperative conditions. The expansion of treatments across various conditions increases the potential for antiemetics in broader therapeutic areas.
For instance, to address motion sickness in travelers, Runway Health offers a scopolamine patch that provides continuous relief from symptoms. A single patch is effective for an extended duration of up to 72 hours.
By End-Use
The antiemetics market by end-use is divided into hospitals, clinics, and home care settings. Hospitals hold the largest share, driven by the high incidence of cancer treatments and surgical procedures requiring antiemetic drugs. Clinics also contribute significantly to the market, as more patients seek outpatient care for nausea management. The home care segment is experiencing growth as patients seek more convenient and cost-effective treatment options, such as oral disintegrating tablets and transdermal patches, which improve treatment accessibility. This trend is expected to drive future growth in the end-use segment.
Segmentations:
By Drug Type:
Serotonin Antagonists
Dopamine Antagonists
Antihistamines
Others
By Application:
Chemotherapy-induced Nausea and Vomiting
Motion Sickness
Other Medical Conditions
By End-Use:
Hospitals
Clinics
Home Care Settings
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Regional Analysis:
North America: Market Leadership
North America holds the largest share of the antiemetics market, accounting for 35% of the global market. The region’s advanced healthcare infrastructure and high healthcare expenditure contribute significantly to its market dominance. Major pharmaceutical companies and research institutions in the U.S. drive the development of innovative antiemetic drugs, addressing the needs of chemotherapy patients and individuals with gastrointestinal disorders. The prevalence of cancer and other conditions that induce nausea continues to support the demand for antiemetics. The increasing adoption of novel drug delivery systems and greater patient awareness further strengthen market growth in this region.
Europe: Strong Market Performance
Europe commands a substantial share, contributing 27% to the global antiemetics market. The increasing incidence of cancer and chronic gastrointestinal diseases across the region is fueling the demand for effective antiemetic treatments. The healthcare system in Europe supports the availability and accessibility of innovative antiemetic drugs, benefiting from strong regulatory frameworks. Countries such as Germany, France, and the UK are seeing an increase in the number of patients requiring these therapies. The market continues to expand as governments invest in healthcare policies that encourage the development and adoption of advanced treatments for nausea and vomiting.
Asia-Pacific: Rapid Growth and Expansion
The Asia-Pacific region is projected to witness the highest market growth rate, capturing 25% of the global antiemetics market. With increasing urbanization, rising healthcare access, and a growing burden of diseases such as cancer and gastrointestinal disorders, demand for antiemetic therapies is surging. Countries like China, India, and Japan are investing heavily in healthcare infrastructure, driving the need for effective antiemetic treatments. The region’s large, underserved population and expanding healthcare sector present significant growth opportunities for antiemetic drug manufacturers. Increased awareness and adoption of modern medical treatments further enhance the region’s market potential.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The antiemetics market is highly competitive, with key players striving to develop innovative and effective treatment options. Major pharmaceutical companies dominate the market, including GlaxoSmithKline, Merck & Co., and Roche, which are known for their strong portfolios of antiemetic drugs targeting chemotherapy-induced nausea and vomiting. These companies are investing heavily in research and development to introduce novel drug formulations and advanced delivery systems like oral disintegrating tablets and transdermal patches. Generic drug manufacturers also play a significant role in driving market competition by providing cost-effective alternatives. The market is witnessing the entry of small and mid-sized companies focusing on niche therapeutic areas, such as motion sickness and postoperative nausea, contributing to the overall growth. Strategic partnerships, acquisitions, and collaborations are common strategies among market players to expand their product offerings and strengthen their market position. The increasing demand for personalized treatments further intensifies the competition within the antiemetics market.
Recent Developments:
In August 2025, Pfizer and Astellas Pharma announced positive results from a Phase 3 trial of PADCEV™ (enfortumab vedotin) combined with KEYTRUDA™ (pembrolizumab) for muscle-invasive bladder cancer.
In May 2025, Cipla launched the antibiotic ZEMDRI® (plazomicin) in India to treat complex urinary tract infections.
In July 2025, Johnson & Johnson MedTech entered into a strategic agreement with Pacira BioSciences to co-promote ZILRETTA®, an injectable for osteoarthritis knee pain.
Market Concentration & Characteristics:
The antiemetics market is moderately concentrated, with a few key players holding significant market shares. Major pharmaceutical companies such as GlaxoSmithKline, Merck & Co., and Roche lead the market, driven by their robust product portfolios and extensive research capabilities. While large firms dominate the chemotherapy-induced nausea and vomiting segment, generic drug manufacturers also hold a considerable share by offering affordable alternatives. Smaller companies focusing on specialized applications like motion sickness and gastrointestinal disorders contribute to market diversification. The market is characterized by continuous innovation, with ongoing developments in drug delivery systems and personalized treatments. Intense competition exists, with companies striving to differentiate through product efficacy, safety profiles, and cost-effectiveness. As demand for more patient-centric solutions grows, the market is expected to see increased collaboration, mergers, and acquisitions to expand product offerings and strengthen market positions.
Report Coverage:
The research report offers an in-depth analysis based on Drug Type, Application, End-Use and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
The antiemetics market is expected to see continued growth driven by advancements in drug formulations and delivery systems.
Demand for chemotherapy-induced nausea treatments will remain strong due to the rising number of cancer patients worldwide.
Increased awareness of antiemetic treatments will expand patient access and drive adoption across various therapeutic areas.
Technological innovations such as oral disintegrating tablets and transdermal patches will enhance patient compliance and treatment convenience.
The market will experience growth in personalized medicine, with therapies tailored to individual patient needs improving treatment outcomes.
The increasing prevalence of lifestyle diseases like obesity and gastrointestinal disorders will contribute to a rise in antiemetic drug demand.
Emerging markets, particularly in Asia-Pacific, will present significant growth opportunities due to expanding healthcare infrastructure and rising disease burdens.
The shift towards over-the-counter antiemetic options will continue, offering competition to prescription medications.
Regulatory advancements and faster drug approval processes will support the development of new antiemetic drugs.
Ongoing collaboration and strategic partnerships among key players will enhance product offerings and strengthen market position.
For Table OF Content – Request For Sample Report –
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Antiemetics, and what is its projected size in 2032?
The Antiemetics market was valued at USD 5125.4 million in 2024 and is anticipated to reach USD 9005.9 million by 2032.
Which Antiemetics market segment held the largest share in 2024?
The chemotherapy-induced nausea and vomiting segment held the largest share in 2024.
What are the primary factors fueling the growth of the Antiemetics market?
Key drivers include a growing patient base undergoing chemotherapy, rising lifestyle diseases, increased awareness of antiemetic treatments, and advancements in drug delivery systems.
Who are the leading companies in the Antiemetics market?
Leading companies in the Antiemetics market include GlaxoSmithKline, Merck & Co., and Roche.
About Author
Rajdeep Kumar Deb
Lead Analyst – Consumer & Finance
Rajdeep brings a decade of consumer goods and financial services insight to strategic market analysis.
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
